Kang EH, Lee EB, Shin KC, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis[J]. Rheumatology (Oxford), 2005, 44(10): 1282-1286.
[2]
Mukae H, Ishimoto H, Sakamoto N, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis[J]. Chest, 2009, 136(5): 1341-1347.
[3]
Sontheimer RD, Miyagawa S. Potentially fatal interstitial lung disease can occur in clinically amyopathic dermatomyositis[J]. J Am Acad Dermatol, 2003, 48(5): 797-798.
[4]
Lee CS, Chen TL, Tzen CY, et al. Idiopathic inflammatory myopathy with diffuse alveolar damage[J]. Clin Rheumatol, 2002, 21(5): 391-396.
[5]
Ye S, Chen XX, Lu XY, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study[J]. Clin Rheumatol, 2007, 26(10): 1647-1654.
[6]
Ji SY, Zeng FQ, Guo Q, et al. Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study[J]. Chin Med J (Engl), 2010, 123(5): 517-522.
[7]
Hengstman GJ, van Engelen BG, van Venrooij WJ. Myositis specific autoantibodies: changing insights in pathophysiology and clinical associations[J]. Curr Opin Rheumatol, 2004, 16(6): 692-699.
[8]
Mimori T, Imura Y, Nakashima R, et al. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance[J]. Curr Opin Rheumatol, 2007, 19(6): 523-529.
[9]
Dankó K, Ponyi A, Constantin T, et al. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases[J]. Medicine (Baltimore), 2004, 83(1): 35-42.
[10]
Marie I, Hatron PY, Hachulla E, et al. Pulmonary involvement in polymyositis and in dermatomyositis[J]. J Rheumatol, 1998, 25(7): 1336-1343.
[11]
Fathi M, Dastmalchi M, Rasmussen E, et al. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis[J]. Ann Rheum Dis, 2004, 63(3): 297-301.
[12]
Marie I, Hachulla E, Chérin P, et al. Interstitial lung disease in polymyositis and dermatomyositis[J]. Arthritis Rheum, 2002, 47(6): 614-622.
[13]
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts)[J]. N Engl J Med, 1975, 292(7): 344-347.
[14]
Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts)[J]. N Engl J Med, 1975, 292(8): 403-407.
Won Huh J, Soon Kim D, Keun Lee C, et al. Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis[J]. Respir Med, 2007, 101(8): 1761-1769.
[17]
Schwarz MI. The lung in polymyositis[J]. Clin Chest Med, 1998, 19(4): 701-712.
Marie I, Hachulla E, Hatron PY, et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis[J]. J Rheumatol, 2001, 28(10): 2230-2237.
[20]
Marie I, Hatron PY, Levesque H, et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults[J]. Medicine (Baltimore), 1999, 78(3): 139-147.
[21]
Taggart AJ, Finch MB, Courtney PA, et al. Anti Jo-1 myositis. ’Mechanic’s hands’ and interstitial lung disease[J]. Ulster Med J, 2002, 71(1): 68-71.
[22]
Richards TJ, Eggebeen A, Gibson K, et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease[J]. Arthritis Rheum, 2009, 60(7): 2183-2192.
[23]
Schnabel A, Reuter M, Biederer J, et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment[J]. Semin Arthritis Rheum, 2003, 32(5): 273-284.
[24]
Chen IJ, Jan Wu YJ, Lin CW, et al. Interstitial lung disease in polymyositis and dermatomyositis[J]. Clin Rheumatol, 2009, 28(6): 639-646.
